close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ALTERITY THERAPEUTICS LIMITED

< Previous 1 2 Next >
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics to Present at the Biotech Showcase
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Prominently Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Tickers ASX ATHE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today